X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs VENUS REMEDIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA VENUS REMEDIES AJANTA PHARMA/
VENUS REMEDIES
 
P/E (TTM) x 19.6 -8.9 - View Chart
P/BV x 4.5 0.1 3,256.4% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 AJANTA PHARMA   VENUS REMEDIES
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-18
VENUS REMEDIES
Mar-17
AJANTA PHARMA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs1,818143 1,273.1%   
Low Rs1,10665 1,701.5%   
Sales per share (Unadj.) Rs239.5324.2 73.9%  
Earnings per share (Unadj.) Rs52.86.4 823.6%  
Cash flow per share (Unadj.) Rs59.540.6 146.7%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs230.0366.0 62.8%  
Shares outstanding (eoy) m88.7712.34 719.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.10.3 1,904.9%   
Avg P/E ratio x27.716.2 170.9%  
P/CF ratio (eoy) x24.62.6 959.5%  
Price / Book Value ratio x6.40.3 2,239.3%  
Dividend payout %00-   
Avg Mkt Cap Rs m129,7821,282 10,122.4%   
No. of employees `0006.80.9 752.5%   
Total wages/salary Rs m3,765251 1,499.9%   
Avg. sales/employee Rs Th3,128.44,430.1 70.6%   
Avg. wages/employee Rs Th554.0278.0 199.3%   
Avg. net profit/employee Rs Th689.787.6 787.3%   
INCOME DATA
Net Sales Rs m21,2584,000 531.4%  
Other income Rs m24223 1,064.3%   
Total revenues Rs m21,4994,023 534.4%   
Gross profit Rs m6,584785 839.0%  
Depreciation Rs m596422 141.3%   
Interest Rs m4344 1.2%   
Profit before tax Rs m6,22642 14,787.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,539-37 -4,159.7%   
Profit after tax Rs m4,68679 5,924.7%  
Gross profit margin %31.019.6 157.9%  
Effective tax rate %24.7-87.9 -28.1%   
Net profit margin %22.02.0 1,114.9%  
BALANCE SHEET DATA
Current assets Rs m12,2362,606 469.5%   
Current liabilities Rs m3,4611,980 174.7%   
Net working cap to sales %41.315.6 263.8%  
Current ratio x3.51.3 268.7%  
Inventory Days Days60128 46.9%  
Debtors Days Days8443 195.8%  
Net fixed assets Rs m11,1405,353 208.1%   
Share capital Rs m177123 143.4%   
"Free" reserves Rs m20,2374,393 460.7%   
Net worth Rs m20,4144,516 452.0%   
Long term debt Rs m101,618 0.6%   
Total assets Rs m24,4868,291 295.3%  
Interest coverage x1,519.41.1 135,361.0%   
Debt to equity ratio x00.4 0.1%  
Sales to assets ratio x0.90.5 179.9%   
Return on assets %19.25.1 375.6%  
Return on equity %23.01.8 1,310.7%  
Return on capital %30.56.3 485.0%  
Exports to sales %00-   
Imports to sales %018.4 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA736 0.0%   
Fx inflow Rs m11,6670-   
Fx outflow Rs m1,616736 219.4%   
Net fx Rs m10,052-736 -1,365.2%   
CASH FLOW
From Operations Rs m2,854997 286.2%  
From Investments Rs m-2,604-461 564.5%  
From Financial Activity Rs m-2-571 0.4%  
Net Cashflow Rs m248-35 -706.8%  

Share Holding

Indian Promoters % 73.8 32.9 224.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 0.2 861.1%  
FIIs % 7.6 0.6 1,310.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 66.4 25.6%  
Shareholders   20,968 20,121 104.2%  
Pledged promoter(s) holding % 4.4 36.4 12.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   STERLING BIOTECH  SANOFI INDIA  ALKEM LABORATORIES  ORCHID PHARMA LTD  PFIZER  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 219 Points Lower; Energy and Auto Stocks Witness Selling(Closing)

After witnessing volatile trades during the day, Indian share markets ended their session on a negative note. Losses were largely seen in the oil & gas sector, auto sector.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2%

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

This Behaviour is Injurious to Wealth Building(Sector Info)

Jun 13, 2018

Blindly following the herd can be the biggest wealth destroyer.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jun 25, 2018 03:35 PM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS